Searched for
DIVIS LABORATORIES LTD
Reliance Industries among 6 largecap stocks showing bullish RSI upswingSix largecap stocks featured in the RSI Trending Up scan on June 16, indicating improving price momentum across select counters. The signal...- Sunil Singhania-backed Abakkus Small Cap Fund adds 3 new stocks, increases stake in HDFC Bank, SBI and 49 othersSunil Singhania's Abakkus Small Cap Fund added three new stocks in May, including Tanla Platforms and Intellect Design Arena. The fund also...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- More women CXOs join India’s million-dollar pay club as domestic firms lead compensation growthNine women now earn over one million dollars annually as C-suite executives. Domestic companies are leading this rise, reflecting a focus o...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Divi's Laboratories Q4 Results: Cons PAT grows 13% YoY to Rs 751 crore, revenue up 10%; Rs 30 per share dividend announcedDivi's Laboratories Q4 Results: Divi's Laboratories announced strong financial results for the March quarter. Net profit rose 13% to Rs 751...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Positive Breakout: These 8 stocks cross above their 200 DMAsAs long as the stock is priced above the 200-day SMA on the daily timeframe, it is generally considered to be in an overall uptrend.
- Sell Divi's Laboratories, target price Rs 4,500: ICICI SecuritiesICICI Securities recommends a sell on Divi's Laboratories with a target price of Rs 4,500 despite recent quarterly growth. Management remai...
- Divis Labs shares 0.39% as Nifty dropsA total of 4,161 shares changed hands on the counter till 11:35AM (IST).
- Share price of Divis Labs as Sensex gains 517.06 pointsPromoters held 51.89 per cent stake in the company as of 30-Sep-2024, while FII and DII ownership stood at 17.25 per cent and 11.92 per cen...
- Divis Labs stock price 2.63 per cent as SensexAs of 30-Sep-2024, promoters held 51.89 per cent stake in the company, while FIIs held 17.25 per cent and domestic institutional investors ...
- Shares of Divis Labs rise as Nifty gainsOn the technical charts, the 200-day moving average of the stock stood at Rs 4002.39.
- Divis Labs rises 0.24% as Sensex climbsThe stock traded at a P/E multiple of 74.11, while the price-to-book value ratio stood at 6.71.
- Share price of Divis Labs rises as Nifty strengthensA total of 5,144 shares changed hands on the counter till 12:58PM (IST).
- Buy Divi's Laboratories, target price Rs 3742: ICICI DirectDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 98115.86 Crore) operating in Pharmace...
- Buy Divi's Laboratories, target price Rs 3762: ICICI DirectDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 99034.38 Crore) operating in Pharmace...
- Buy Divi's Laboratories, target price Rs 4130: Religare BrokingPromoters held 51.93 per cent stake in the company as of 30-Jun-2023, while FIIs owned 14.69 per cent, DIIs 21.03 per cent.
Load More
